Erin H Amerson, MD
Dermatology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 2
- Since medical school
- 22 years
- Medical College of Wisconsin, 2004
Offices
2 locations · UCSF Medical Group Business Services · University of California Sfgh Medical Group
Hospitals listed: UCSF Medical Center · Zuckerberg San Francisco General Hosp & Trauma Ctr. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Amerson’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A105532 · Current
Licensed to practise in California · since 2008 · expires 2028-03-31 · Medical College of Wisconsin.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Dermatology - Dermatology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
- Zuckerberg San Francisco General Hosp & Trauma CtrSan Francisco, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of San Francisco Health Network, which runs 2 hospitalsPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.449, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.37, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.538, Oct 2024 – Sep 2025
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Zuckerberg San Francisco General Hosp & Trauma Ctr
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.449 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.37 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.538 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.91) · 667 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.12 (0.76 to 1.49) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 195.34 (147.34 to 243.34) · 76 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 114 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.5 · 201 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.5 · 214 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 261 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 1,351 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.07 to 0.5) · 4,709 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.39 (0.19 to 0.59) · 4,644 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.34 (2.11 to 6.56) · 795 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0 to 3.28) · 234 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.85 (1.33 to 4.38) · 861 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.95 (0.25 to 17.64) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6 (2.01 to 9.98) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 167 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.79 (0.08 to 1.49) · 4,129 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.709 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.769 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 41 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 227 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 28.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 75.1 · 239 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.2 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.3 (8.3 to 15.1) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 132 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.4 to 17.9) · 966 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.7) · 88 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,644 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$70,634
Medicare paid this office $70,634 for 210 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 125 | $18,913 | $110 |
| Destruction of skin growth, 1-14 growths | 98 | $14,928 | $111 |
| Short return visit (20+ min) | 104 | $9,949 | $78 |
| Destruction of precancer skin growth, 1 growth | 96 | $5,923 | $44 |
| Destruction of precancer skin growth, 15 or more growths | 20 | $5,708 | $159 |
See all 10 services
| Return visit (30+ min) | 125 | $18,913 | $110 |
| Destruction of skin growth, 1-14 growths | 98 | $14,928 | $111 |
| Short return visit (20+ min) | 104 | $9,949 | $78 |
| Destruction of precancer skin growth, 1 growth | 96 | $5,923 | $44 |
| Destruction of precancer skin growth, 15 or more growths | 20 | $5,708 | $159 |
| Biopsy of related skin growth, first growth | 44 | $4,019 | $76 |
| Destruction of precancer skin growth, 2-14 growths | 82 | $3,692 | $7 |
| New patient visit (45+ min) | 12 | $1,722 | $144 |
| Biopsy of related skin growth, each additional growth | 15 | $1,328 | $51 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 13 | $236 | $13 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 473 | More than 86% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 64 | More than 71% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 132 | 122 | 256 | 399 | 480 | 552 |
| Destruction of precancer skin growth, 1 growth | 44 | 39 | 69 | 91 | 114 | 135 |
| Destruction of skin growth, 1-14 growths | 38 | 29 | 50 | 72 | 84 | 135 |
| Biopsy of related skin growth, first growth | 27 | 17 | 24 | 44 | 48 | 53 |
| Destruction of precancer skin growth, 15 or more growths | – | – | – | 14 | 35 | 36 |
| Biopsy of related skin growth, each additional growth | – | – | – | – | 16 | 26 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
210 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 6% · Women 63% · Also on Medicaid 11% · Health risk score 0.99. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 56% · Cancer 20% · Coronary heart disease 18% · Depression 17% · Diabetes 14% · Chronic kidney disease 14% · Atrial fibrillation 11% · Heart failure 6% · COPD 6%.
The office billed $442,603, Medicare allowed $96,272 and paid $70,634; for 1,332 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 210 | 1,332 | 74 | 0.99 | $442,603 | $70,634 |
| 2023 | 209 | 1,133 | 74 | 1.03 | $378,650 | $61,008 |
| 2022 | 205 | 970 | 74 | 0.98 | $316,821 | $50,666 |
| 2021 | 141 | 647 | 72 | 1.00 | $211,729 | $34,046 |
| 2020 | 112 | 407 | 71 | 1.33 | $129,821 | $19,282 |
| 2019 | 115 | 471 | 70 | 1.32 | $164,031 | $24,741 |
| 2018 | 89 | 345 | 72 | 1.56 | $116,279 | $13,525 |
| 2017 | 51 | 300 | 73 | 1.30 | $74,471 | $6,698 |
| 2016 | 57 | 313 | 71 | 1.28 | $87,079 | $8,168 |
| 2015 | 54 | 327 | 69 | 1.53 | $79,430 | $7,479 |
| 2014 | 52 | 216 | 70 | 0.99 | $52,244 | $4,700 |
| 2013 | 45 | 214 | 73 | 1.02 | $48,853 | $5,081 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 123 | $18,843 | $111 |
| Destruction of skin growth, 1-14 growths | 72 | $9,178 | $109 |
| Short return visit (20+ min) | 62 | $5,634 | $77 |
| Destruction of precancer skin growth, 15 or more growths | 23 | $5,611 | $160 |
| Destruction of precancer skin growth, 1 growth | 94 | $5,021 | $44 |
| Biopsy of related skin growth, first growth | 41 | $4,200 | $87 |
| Destruction of precancer skin growth, 2-14 growths | 72 | $3,163 | $7 |
| New patient visit (45+ min) | 18 | $2,463 | $137 |
| Biopsy of related skin growth, each additional growth | 11 | $829 | $52 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 15 | $262 | $12 |
2022: 10 services
| Return visit (30+ min) | 97 | $13,694 | $110 |
| Destruction of skin growth, 1-14 growths | 65 | $7,945 | $110 |
| Short return visit (20+ min) | 66 | $5,626 | $74 |
| Biopsy of related skin growth, first growth | 40 | $3,939 | $90 |
| Destruction of precancer skin growth, 1 growth | 78 | $3,852 | $42 |
| New patient visit (45+ min) | 25 | $3,325 | $133 |
| Destruction of precancer skin growth, 2-14 growths | 62 | $2,571 | $6 |
| Destruction of precancer skin growth, 15 or more growths | 13 | $2,365 | $169 |
| New patient visit (30+ min) | 21 | $1,987 | $95 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 22 | $316 | $14 |
2021: 8 services
| Short return visit (20+ min) | 71 | $6,698 | $76 |
| Return visit (30+ min) | 35 | $5,784 | $116 |
| Destruction of skin growth, 1-14 growths | 41 | $5,035 | $101 |
| New patient visit (30+ min) | 33 | $3,237 | $98 |
| Destruction of precancer skin growth, 1 growth | 58 | $3,008 | $44 |
| Biopsy of related skin growth, first growth | 21 | $2,017 | $84 |
| New patient visit (45+ min) | 11 | $1,649 | $150 |
| Destruction of precancer skin growth, 2-14 growths | 47 | $1,593 | $6 |
2020: 6 services
| Short return visit (20+ min) | 66 | $6,047 | $64 |
| Destruction of skin growth, 1-14 growths | 24 | $3,075 | $106 |
| New patient visit (15+ min) | 29 | $1,605 | $55 |
| Destruction of precancer skin growth, 1 growth | 32 | $1,405 | $36 |
| Biopsy of related skin growth, first growth | 15 | $1,332 | $78 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $689 | $6 |
2019: 6 services
| Short return visit (20+ min) | 65 | $7,300 | $68 |
| Destruction of skin growth, 1-14 growths | 30 | $3,776 | $99 |
| New patient visit (15+ min) | 44 | $2,696 | $61 |
| Biopsy of related skin growth, first growth | 24 | $2,211 | $82 |
| Destruction of precancer skin growth, 1 growth | 37 | $1,913 | $43 |
| Destruction of precancer skin growth, 2-14 growths | 27 | $690 | $5 |
2018: 6 services
| Short return visit (20+ min) | 47 | $3,315 | $47 |
| Destruction of skin growth, 1-14 growths | 22 | $1,956 | $72 |
| New patient visit (15+ min) | 31 | $1,880 | $61 |
| Biopsy of single growth of skin and/or tissue | 18 | $1,177 | $62 |
| Destruction of precancer skin growth, 1 growth | 24 | $1,000 | $37 |
| Destruction of precancer skin growth, 2-14 growths | 18 | $318 | $3 |
2017: 5 services
| Short return visit (20+ min) | 36 | $2,073 | $41 |
| Destruction of skin growth, 1-14 growths | 16 | $1,309 | $62 |
| Destruction of precancer skin growth, 1 growth | 23 | $1,005 | $35 |
| Biopsy of single growth of skin and/or tissue | 12 | $290 | $24 |
| Destruction of precancer skin growth, 2-14 growths | 20 | $271 | $2 |
2016: 6 services
| Short return visit (20+ min) | 42 | $2,652 | $43 |
| Destruction of skin growth, 1-14 growths | 17 | $1,154 | $61 |
| Destruction of precancer skin growth, 1 growth | 24 | $1,135 | $34 |
| New patient visit (15+ min) | 17 | $678 | $40 |
| Biopsy of single growth of skin and/or tissue | 17 | $558 | $28 |
| Destruction of precancer skin growth, 2-14 growths | 18 | $212 | $2 |
2015: 6 services
| Short return visit (20+ min) | 41 | $2,617 | $40 |
| Destruction of skin growth, 1-14 growths | 17 | $1,209 | $67 |
| Destruction of precancer skin growth, 1 growth | 19 | $1,079 | $37 |
| New patient visit (15+ min) | 13 | $535 | $41 |
| Biopsy of single growth of skin and/or tissue | 12 | $468 | $28 |
| Destruction of precancer skin growth, 2-14 growths | 18 | $272 | $2 |
2014: 4 services
| Short return visit (20+ min) | 41 | $1,966 | $41 |
| Destruction of precancer skin growth, 1 growth | 16 | $633 | $35 |
| Biopsy of single growth of skin and/or tissue | 13 | $361 | $28 |
| Destruction of precancer skin growth, 2-14 growths | 16 | $176 | $2 |
2013: 5 services
| Short return visit (20+ min) | 27 | $1,259 | $32 |
| Destruction of precancer skin growth, 1 growth | 17 | $815 | $39 |
| Biopsy of single growth of skin and/or tissue | 14 | $352 | $25 |
| Destruction of precancer skin growth, 2-14 growths | 16 | $340 | $4 |
| New patient visit (15+ min) | 12 | $218 | $18 |
Medicaid work
$508,398 in 2024
Medicaid paid $508,398 for 3,378 billed services this clinician did in 2024, up to 119 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,493 | $505,945 |
| Short return visit (20+ min) | 386 | $1,225 |
| Return visit (30+ min) | 297 | $742 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | 14 | $364 |
| New patient visit (30+ min) | 28 | $81 |
| Short return visit | 15 | $41 |
| Actinotherapy (ultraviolet light) | 327 | $0 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 29 | $0 |
| Service | 789 | $0 |
| 2024 | 3,378 | 9 | 119 | $508,398 |
| 2023 | 3,008 | 9 | 98 | $314,899 |
| 2022 | 2,573 | 6 | 98 | $248,975 |
| 2021 | 2,799 | 4 | 98 | $296,940 |
| 2020 | 1,630 | 4 | 86 | $201,344 |
| 2019 | 787 | 3 | 104 | $193,107 |
| 2018 | 1,421 | 2 | 154 | $371,333 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 969 | $313,601 |
| Short return visit (20+ min) | 662 | $761 |
| Return visit (30+ min) | 374 | $538 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 13 | $0 |
| New patient visit (30+ min) | 26 | $0 |
| OFF/OP EST MAY X REQ PHY/QHP | 13 | $0 |
| Short return visit | 12 | $0 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 89 | $0 |
| Service | 850 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 776 | $247,481 |
| Short return visit (20+ min) | 1,005 | $1,337 |
| New patient visit (30+ min) | 40 | $156 |
| Return visit (30+ min) | 27 | $0 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 43 | $0 |
| Service | 682 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 940 | $293,993 |
| Short return visit (20+ min) | 1,025 | $2,713 |
| Short return visit | 98 | $234 |
| Service | 736 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 667 | $200,669 |
| Short return visit (20+ min) | 553 | $667 |
| OFF/OP EST MAY X REQ PHY/QHP | 28 | $8 |
| Service | 382 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 639 | $192,878 |
| Short return visit (20+ min) | 83 | $230 |
| Service | 65 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 1,226 | $370,430 |
| Short return visit (20+ min) | 195 | $903 |
Drugs they prescribed that Part D paid
$2,954,961
Pharmacies billed $2,954,961 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,555) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,128 generic and fewer than 11 brand-name prescriptions · $2,954,961 in drug cost · 55 antibiotic prescriptions to 19 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Skyrizi | 24 | $439,228 | $18,301 |
| Dupixent | 102 | $355,737 | $3,488 |
| Humira(Cf) | 26 | $331,825 | $12,762 |
| Humira | 35 | $308,468 | $8,813 |
| Cosentyx Sensoready (2 Pens) | 19 | $178,280 | $9,383 |
See all 41 drugs
| Skyrizi | 24 | $439,228 | $18,301 |
| Dupixent | 102 | $355,737 | $3,488 |
| Humira(Cf) | 26 | $331,825 | $12,762 |
| Humira | 35 | $308,468 | $8,813 |
| Cosentyx Sensoready (2 Pens) | 19 | $178,280 | $9,383 |
| Dupixent | 50 | $171,068 | $3,421 |
| Taltz | 15 | $97,356 | $6,490 |
| Otezla | 13 | $60,694 | $4,669 |
| Siliq | 11 | $54,808 | $4,983 |
| Opzelura | 18 | $52,422 | $2,912 |
| Zoryve | 13 | $11,153 | $858 |
| Tacrolimus | 35 | $5,443 | $156 |
| Acitretin | 11 | $4,698 | $427 |
| Ketoconazole | 178 | $3,792 | $21 |
| Clobetasol Propionate | 72 | $3,251 | $45 |
| Fluocinonide | 55 | $2,669 | $49 |
| Calcipotriene | 15 | $2,291 | $153 |
| Triamcinolone Acetonide | 135 | $2,249 | $17 |
| Fluorouracil | 29 | $2,198 | $76 |
| Metronidazole | 31 | $1,522 | $49 |
| Betamethasone Dipropionate | 42 | $1,457 | $35 |
| Methotrexate | 61 | $1,035 | $17 |
| Fluocinolone Acetonide | 12 | $937 | $78 |
| Betamethasone Diprop Augmented | 11 | $847 | $77 |
| Clindamycin | 15 | $843 | $56 |
| Fluocinolone Acetonide | 12 | $713 | $59 |
| Cephalexin | 18 | $609 | $34 |
| Doxycycline Hyclate | 17 | $605 | $36 |
| Clindamycin Phosphate | 19 | $429 | $23 |
| Minoxidil | 48 | $403 | $8 |
| Spironolactone | 23 | $398 | $17 |
| Mycophenolate Mofetil | 11 | $396 | $36 |
| Econazole Nitrate | 14 | $375 | $27 |
| Hydroxyzine | 19 | $327 | $17 |
| Hydroxychloroquine Sulfate | 11 | $316 | $29 |
| Hydrocortisone | 62 | $286 | $5 |
| Clotrimazole | 15 | $242 | $16 |
| Mupirocin | 29 | $237 | $8 |
| Dutasteride | 14 | $228 | $16 |
| Terbinafine | 22 | $216 | $10 |
| Prednisone | 20 | $68 | $3 |
Year by year
| 2024 | 1,555 | 364 | 0% (0) | None | $2,954,961 |
| 2023 | 1,631 | 356 | 0% (0) | 25% | $3,836,038 |
| 2022 | 1,342 | 327 | 0% (0) | 19% | $2,706,269 |
| 2021 | 1,086 | 276 | 0% (0) | 14% | $1,262,034 |
| 2020 | 1,077 | 276 | 0% (0) | 11% | $567,580 |
| 2019 | 1,328 | 339 | 0% (0) | 12% | $844,117 |
| 2018 | 1,152 | 283 | 0% (0) | None | $494,241 |
| 2017 | 691 | 211 | 0% (0) | 8% | $125,726 |
| 2016 | 789 | 219 | 0% (0) | 10% | $217,762 |
| 2015 | 335 | 107 | None | None | $76,172 |
| 2014 | 262 | 99 | 0% (0) | None | $32,361 |
| 2013 | 205 | 82 | 0% (0) | None | $14,904 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 38 drugs
| Humira(Cf) | None | 78 | $837,964 | $10,743 |
| Gammaked | Immune globulin | 13 | $615,207 | $47,324 |
| Humira | None | 47 | $528,838 | $11,252 |
| Skyrizi | None | 20 | $431,088 | $21,554 |
| Dupixent | None | 101 | $386,653 | $3,828 |
| Cosentyx Sensoready (2 Pens) | None | 20 | $219,874 | $10,994 |
| Stelara | None | 15 | $214,957 | $14,330 |
| Dupixent | None | 29 | $117,124 | $4,039 |
| Clobetasol Propionate | None | 71 | $13,363 | $188 |
| Acitretin | None | 13 | $9,710 | $747 |
| Tacrolimus | None | 38 | $9,056 | $238 |
| Fluocinonide | None | 98 | $8,009 | $82 |
| Calcipotriene | None | 19 | $6,207 | $327 |
| Entecavir | None | 17 | $6,066 | $357 |
| Doxycycline Hyclate | None | 32 | $5,240 | $164 |
| Ketoconazole | None | 173 | $4,356 | $25 |
| Halobetasol Propionate | None | 30 | $3,919 | $131 |
| Triamcinolone Acetonide | None | 141 | $3,239 | $23 |
| Betamethasone Dipropionate | None | 36 | $2,575 | $72 |
| Methotrexate | None | 67 | $2,521 | $38 |
| Fluorouracil | None | 23 | $2,123 | $92 |
| Metronidazole | None | 24 | $1,875 | $78 |
| Mycophenolate Mofetil | None | 19 | $1,766 | $93 |
| Hydroxychloroquine Sulfate | None | 15 | $1,067 | $71 |
| Betamethasone Diprop Augmented | None | 22 | $1,016 | $46 |
| Clindamycin Phosphate | None | 20 | $896 | $45 |
| Hydrocortisone | None | 85 | $833 | $10 |
| Sulfamethoxazole-Trimethoprim | None | 12 | $533 | $44 |
| Valacyclovir | None | 13 | $533 | $41 |
| Econazole Nitrate | None | 13 | $511 | $39 |
| Clotrimazole | None | 16 | $485 | $30 |
| Spironolactone | None | 20 | $481 | $24 |
| Terbinafine | None | 11 | $454 | $41 |
| Hydroxyzine | None | 17 | $434 | $26 |
| Gabapentin | None | 12 | $413 | $34 |
| Minoxidil | None | 26 | $343 | $13 |
| Mupirocin | None | 23 | $276 | $12 |
| Prednisone | None | 22 | $225 | $10 |
2022: 29 drugs
| Humira | None | 30 | $689,565 | $22,986 |
| Gammaked | Immune globulin | 16 | $508,078 | $31,755 |
| Humira(Cf) | None | 59 | $467,010 | $7,915 |
| Stelara | None | 22 | $301,435 | $13,702 |
| Cosentyx Pen (2 Pens) | None | 12 | $150,665 | $12,555 |
| Dupixent | None | 27 | $95,278 | $3,529 |
| Clobetasol Propionate | None | 86 | $10,600 | $123 |
| Fluocinonide | None | 128 | $9,552 | $75 |
| Acitretin | None | 16 | $9,322 | $583 |
| Entecavir | None | 14 | $7,970 | $569 |
| Tacrolimus | None | 31 | $6,907 | $223 |
| Halobetasol Propionate | None | 39 | $5,412 | $139 |
| Betamethasone Dipropionate | None | 56 | $4,896 | $87 |
| Ketoconazole | None | 111 | $3,032 | $27 |
| Doxycycline Hyclate | None | 34 | $2,763 | $81 |
| Triamcinolone Acetonide | None | 146 | $2,532 | $17 |
| Metronidazole | None | 21 | $1,765 | $84 |
| Betamethasone Diprop Augmented | None | 19 | $1,620 | $85 |
| Fluorouracil | None | 12 | $1,557 | $130 |
| Clindamycin Phosphate | None | 29 | $1,539 | $53 |
| Mycophenolate Mofetil | None | 20 | $1,469 | $73 |
| Methotrexate | None | 21 | $911 | $43 |
| Hydroxyzine | None | 22 | $598 | $27 |
| Clotrimazole | None | 21 | $579 | $28 |
| Hydrocortisone | None | 67 | $568 | $8 |
| Econazole Nitrate | None | 13 | $471 | $36 |
| Spironolactone | None | 11 | $262 | $24 |
| Prednisone | None | 22 | $250 | $11 |
| Mupirocin | None | 13 | $109 | $8 |
2021: 24 drugs
| Humira | 12 | $301,658 | $25,138 |
| Humira(Cf) | 29 | $233,817 | $8,063 |
| Acitretin | 14 | $7,894 | $564 |
| Fluocinonide | 101 | $6,325 | $63 |
| Doxycycline Hyclate | 21 | $4,845 | $231 |
| Clobetasol Propionate | 64 | $4,640 | $73 |
| Halobetasol Propionate | 37 | $4,356 | $118 |
| Tacrolimus | 20 | $3,454 | $173 |
| Betamethasone Dipropionate | 34 | $2,652 | $78 |
| Mycophenolate Mofetil | 15 | $2,464 | $164 |
| Triamcinolone Acetonide | 162 | $2,453 | $15 |
| Ketoconazole | 92 | $2,103 | $23 |
| Metronidazole | 23 | $1,662 | $72 |
| Hydroxychloroquine Sulfate | 18 | $1,536 | $85 |
| Betamethasone Diprop Augmented | 16 | $1,257 | $79 |
| Econazole Nitrate | 23 | $826 | $36 |
| Clindamycin Phosphate | 20 | $712 | $36 |
| Methotrexate | 18 | $579 | $32 |
| Valacyclovir | 13 | $539 | $41 |
| Clotrimazole | 21 | $505 | $24 |
| Hydrocortisone | 59 | $391 | $7 |
| Spironolactone | 12 | $300 | $25 |
| Hydroxyzine | 24 | $266 | $11 |
| Prednisone | 14 | $122 | $9 |
2020: 22 drugs
| Dupixent | 20 | $63,600 | $3,180 |
| Tacrolimus | 34 | $9,929 | $292 |
| Halobetasol Propionate | 47 | $5,959 | $127 |
| Fluocinonide | 83 | $5,696 | $69 |
| Doxycycline Hyclate | 29 | $5,423 | $187 |
| Clobetasol Propionate | 50 | $4,874 | $97 |
| Tretinoin | 24 | $3,144 | $131 |
| Ketoconazole | 134 | $2,885 | $22 |
| Betamethasone Dipropionate | 25 | $2,692 | $108 |
| Hydroxychloroquine Sulfate | 24 | $2,643 | $110 |
| Triamcinolone Acetonide | 133 | $2,289 | $17 |
| Fluorouracil | 13 | $1,717 | $132 |
| Fluocinolone Acetonide | 12 | $1,593 | $133 |
| Betamethasone Diprop Augmented | 20 | $1,580 | $79 |
| Methotrexate | 37 | $1,311 | $35 |
| Clindamycin Phosphate | 31 | $1,184 | $38 |
| Metronidazole | 11 | $999 | $91 |
| Clotrimazole | 25 | $654 | $26 |
| Gabapentin | 44 | $473 | $11 |
| Hydrocortisone | 65 | $467 | $7 |
| Hydroxyzine | 17 | $150 | $9 |
| Sulfamethoxazole-Trimethoprim | 12 | $86 | $7 |
2019: 30 drugs
| Humira(Cf) | 15 | $157,163 | $10,478 |
| Humira | 14 | $153,359 | $10,954 |
| Humira(Cf) | 15 | $78,690 | $5,246 |
| Dupixent | 15 | $44,727 | $2,982 |
| Halobetasol Propionate | 87 | $15,170 | $174 |
| Tacrolimus | 41 | $9,808 | $239 |
| Acitretin | 17 | $9,060 | $533 |
| Fluocinonide | 93 | $8,020 | $86 |
| Clobetasol Propionate | 42 | $7,158 | $170 |
| Calcipotriene | 23 | $4,748 | $206 |
| Betamethasone Diprop Augmented | 48 | $4,356 | $91 |
| Fluocinolone Acetonide | 17 | $3,837 | $226 |
| Econazole Nitrate | 11 | $3,818 | $347 |
| Triamcinolone Acetonide | 172 | $3,459 | $20 |
| Fluorouracil | 17 | $2,527 | $149 |
| Metronidazole | 20 | $2,402 | $120 |
| Ketoconazole | 105 | $2,211 | $21 |
| Betamethasone Dipropionate | 19 | $1,829 | $96 |
| Clindamycin Phosphate | 28 | $1,697 | $61 |
| Mycophenolate Mofetil | 16 | $1,199 | $75 |
| Methotrexate | 38 | $999 | $26 |
| Doxycycline Monohydrate | 18 | $916 | $51 |
| Gabapentin | 71 | $805 | $11 |
| Clotrimazole | 40 | $784 | $20 |
| Mometasone Furoate | 14 | $733 | $52 |
| Prednisone | 40 | $489 | $12 |
| Hydroxyzine | 31 | $450 | $15 |
| Doxycycline Hyclate | 14 | $420 | $30 |
| Hydrocortisone | 52 | $382 | $7 |
| Mupirocin | 14 | $106 | $8 |
2018: 28 drugs
| Humira | 21 | $140,967 | $6,713 |
| Humira | 21 | $115,651 | $5,507 |
| Halobetasol Propionate | 84 | $14,760 | $176 |
| Clobetasol Propionate | 43 | $8,977 | $209 |
| Fluocinonide | 99 | $8,338 | $84 |
| Acitretin | 16 | $8,159 | $510 |
| Calcipotriene | 21 | $5,016 | $239 |
| Tacrolimus | 21 | $4,908 | $234 |
| Econazole Nitrate | 16 | $4,693 | $293 |
| Ketoconazole | 92 | $3,801 | $41 |
| Betamethasone Diprop Augmented | 39 | $3,695 | $95 |
| Triamcinolone Acetonide | 159 | $3,368 | $21 |
| Fluorouracil | 19 | $2,450 | $129 |
| Methotrexate | 43 | $2,257 | $52 |
| Clindamycin Phosphate | 25 | $2,063 | $83 |
| Hydroxychloroquine Sulfate | 13 | $1,832 | $141 |
| Mycophenolate Mofetil | 11 | $1,532 | $139 |
| Metronidazole | 11 | $1,276 | $116 |
| Doxycycline Hyclate | 17 | $1,147 | $67 |
| Clotrimazole | 26 | $1,011 | $39 |
| Alclometasone Dipropionate | 11 | $984 | $89 |
| Hydroxyzine | 29 | $765 | $26 |
| Hydrocortisone | 58 | $605 | $10 |
| Prednisone | 34 | $358 | $11 |
| Terbinafine | 12 | $291 | $24 |
| Doxepin | 11 | $241 | $22 |
| Gabapentin | 25 | $225 | $9 |
| Sulfamethoxazole-Trimethoprim | 14 | $204 | $15 |
2017: 15 drugs
| Clobetasol Propionate | 46 | $12,228 | $266 |
| Calcipotriene | 24 | $9,512 | $396 |
| Fluocinonide | 75 | $8,162 | $109 |
| Halobetasol Propionate | 41 | $7,912 | $193 |
| Fluorouracil | 19 | $7,430 | $391 |
| Ketoconazole | 69 | $3,094 | $45 |
| Econazole Nitrate | 20 | $2,328 | $116 |
| Triamcinolone Acetonide | 92 | $1,641 | $18 |
| Clindamycin Phosphate | 25 | $1,533 | $61 |
| Alclometasone Dipropionate | 15 | $1,326 | $88 |
| Clotrimazole | 16 | $574 | $36 |
| Hydrocortisone | 38 | $371 | $10 |
| Methotrexate | 12 | $288 | $24 |
| Prednisone | 16 | $206 | $13 |
| Mupirocin | 13 | $160 | $12 |
2016: 18 drugs
| Clobetasol Propionate | 105 | $28,650 | $273 |
| Fluocinonide | 108 | $11,071 | $103 |
| Fluorouracil | 12 | $9,491 | $791 |
| Calcipotriene | 19 | $7,037 | $370 |
| Econazole Nitrate | 24 | $3,061 | $128 |
| Metronidazole | 19 | $2,721 | $143 |
| Clindamycin Phosphate | 25 | $1,911 | $76 |
| Doxycycline Hyclate | 11 | $1,699 | $154 |
| Triamcinolone Acetonide | 83 | $1,640 | $20 |
| Tretinoin | 18 | $1,084 | $60 |
| Alclometasone Dipropionate | 13 | $977 | $75 |
| Ketoconazole | 39 | $878 | $23 |
| Clotrimazole | 16 | $704 | $44 |
| Hydrocortisone | 70 | $647 | $9 |
| Methotrexate | 12 | $417 | $35 |
| Prednisone | 27 | $414 | $15 |
| Hydroxyzine | 13 | $166 | $13 |
| Mupirocin | 16 | $120 | $8 |
2015: 8 drugs
| Clobetasol Propionate | 35 | $9,291 | $265 |
| Econazole Nitrate | 16 | $4,264 | $267 |
| Fluocinonide | 35 | $3,737 | $107 |
| Desonide | 19 | $3,626 | $191 |
| Clindamycin Phosphate | 16 | $1,501 | $94 |
| Triamcinolone Acetonide | 27 | $460 | $17 |
| Prednisone | 15 | $133 | $9 |
| Hydrocortisone | 11 | $69 | $6 |
2014: 9 drugs
| Clobetasol Propionate | 17 | $2,594 | $153 |
| Econazole Nitrate | 35 | $2,428 | $69 |
| Fluocinonide | 33 | $2,213 | $67 |
| Desonide | 11 | $2,121 | $193 |
| Fluocinolone Acetonide | 11 | $1,900 | $173 |
| Doxycycline Hyclate | 13 | $1,535 | $118 |
| Clindamycin Phosphate | 17 | $1,185 | $70 |
| Triamcinolone Acetonide | 29 | $540 | $19 |
| Hydrocortisone | 14 | $138 | $10 |
2013: 8 drugs
| Clobetasol Propionate | 34 | $1,916 | $56 |
| Fluocinonide | 21 | $1,296 | $62 |
| Desonide | 21 | $1,208 | $58 |
| Doxycycline Hyclate | 11 | $727 | $66 |
| Econazole Nitrate | 15 | $382 | $25 |
| Triamcinolone Acetonide | 22 | $315 | $14 |
| Hydroxyzine | 11 | $293 | $27 |
| Hydrocortisone | 12 | $83 | $7 |
Money from drug and device companies
$74 in 2025
A payment is not proof that care is biased.
| Pfizer | Cibinqo | $74 | 1 payment
|
See the published payment
| Pfizer | Meals · 2025-03-07 | Cibinqo | $74 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1679732671
- Licence
- CA A105532California A105532: Current · expires 2028-03-31
- Trained
- Medical College of Wisconsin, 2004 · 22 years ago
- Group
- UCSF Medical Group Business Services · University of California Sfgh Medical Group
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 1701 Divisadero St, 3rd Floor, San Francisco, CA, 94115
- NPI first listed
- 2008-06-04
- NPI last updated
- 2012-02-29
This is when the NPI record was last certified, not a medical board exam.